To analyze the efficacy and safety of icotinib hydrochloride combined with intensity-modulated radiation therapy (IMRT) in the treatment of brain metastases from epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma.
One-hundred cases of brain metastases patients from EGFR mutation-positive lung adenocarcinoma admitted to the first affiliated hospital of Henan university from April 2017 to April 2019 were retrospectively analyzed, and they were divided into the targeted therapy group (n=50) and the combined therapy group (n=50) according to the treatment method. The targeted therapy group were treated with icotinib hydrochloride, and the combined therapy group received IMRT treatment on the basis of the targeted therapy group. After four months of targeted therapy, the short-term curative effects of the two groups were evaluated, the occurrence of adverse reactions in the two groups were counted, the levels of serum tumor markers (carcinoembryonic antigen, carbohydrate antigen 19-9, and cytokeratin 19 fragment antigen 21-1) were detected at the time of enrollment and four months after targeted therapy, and the two-year survival rate was followed up.
The objective remission rate in the combined therapy group was 82.00%, which was significantly higher than 58.00% in the targeted therapy group (P<0.05). The adverse reactions such as rash, nausea and vomiting, fatigue, bone marrow suppression, diarrhea, liver and kidney injury in the two groups were all in the grade Ⅰ to Ⅲ, which were tolerated by the patients. There was no significant difference in the grade of adverse reactions between the two groups (P>0.05). After four months of targeted therapy, the levels of serum tumor markers in the two groups were significantly lower than those in the same group when joining the group (P<0.05), and the combined therapy group were significantly lower than those in the targeted therapy group in the same period (P<0.05). The two-year survival rate of the combined therapy group was 38.00%, which was significantly higher than that in the targeted therapy group (20.00%)(P<0.05).
Icotinib hydrochloride combined with IMRT in the treatment of brain metastasis from EGFR mutation-positive lung adenocarcinoma can achieve better short-term and long-term effects, and the adverse reactions are mild and can tolerated by the patients.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |